Compromised anti-tumor responses in tumor necrosis factor-α knockout mice

被引:9
作者
Baxevanis, CN [1 ]
Voutsas, IF [1 ]
Tsitsilonis, OE [1 ]
Tsiatas, ML [1 ]
Gritzapis, AD [1 ]
Papamichail, M [1 ]
机构
[1] St Savas Canc Hosp, Canc Immunol & Immunotherapy Ctr, GR-11522 Athens, Greece
关键词
TNF knockout; cytotoxicity; tumor model;
D O I
10.1002/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO;2-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The response of lymphokine-activated killer (LAK) and natural killer (NK) cells from mice lacking tumor necrosis factor-alpha (TNF-alpha-/- mice) was impaired in cytotoxicity assays against various tumor cell targets. Furthermore, allogeneic cytotoxic T lymphocyte (CTL) responses were also impaired as compared to TNF-alpha+/+ littermates (control mice). Cytotoxicity was restored both upon in vitro incubation of TNF-alpha-/- lymphocytes with recombinant TNF-alpha (rTNF-alpha) or upon in vivo treatment of TNF-alpha-/- mice with rTNF-alpha. Using combinations of monoclonal antibodies we were able to show that TNF-alpha-/- effector lymphocytes exhibit both perforin- and Fas ligand-based cytotoxicity. Furthermore, upon in vivo administration of rTNF-alpha these effecters, in addition to perforin and Fas ligand, are also armed with TNF-alpha cytotoxic molecules, thus resembling to the cytotoxic effecters from control mice. In a tumor model, immunized TNF-alpha-/- mice failed to reject the syngeneic fibrosarcoma MC57X, but did so when injected with rTNF-alpha. In vivo administration of anti-TNF-alpha mAb neutralized the effect of rTNF-alpha supporting the growth of MC57X cells. Our data provide novel evidence for TNF-alpha as an essential factor in (i) controlling cytotoxicity in vitro and in vivo and (ii) promoting tumor rejection in vivo.
引用
收藏
页码:1957 / 1966
页数:10
相关论文
共 52 条
[1]  
ABBAS AK, 1997, CELLULAR MOL IMMUNOL, P364
[2]  
AREZANASEISDEDO.F, 1988, P NATL ACAD SCI USA, V79, P545
[3]  
ASHER A, 1987, J IMMUNOL, V138, P963
[4]   Antigen processing and presentation in transplantation [J].
Auchincloss, H ;
Sultan, H .
CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (05) :681-687
[5]  
BAXEVANIS CN, 1995, CANCER IMMUNOL IMMUN, V40, P410, DOI 10.1007/s002620050191
[6]  
BAXEVANIS CN, 1990, J IMMUNOL, V144, P4166
[7]   CHARACTERIZATION OF THE ANTITUMOR IMMUNE-RESPONSE IN HUMAN CANCERS AND STRATEGIES FOR IMMUNOTHERAPY [J].
BAXEVANIS, CN ;
PAPAMICHAIL, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1994, 16 (03) :157-179
[8]   Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes [J].
Baxevanis, CN ;
Tsiatas, ML ;
Cacoullos, NT ;
Spanakos, G ;
Liacos, C ;
Missitzis, I ;
Papadhimitriou, SI ;
Papamichail, M .
BRITISH JOURNAL OF CANCER, 1997, 76 (08) :1072-1080
[9]   H-2-CONTROLLED SUPPRESSION OF T-CELL RESPONSE TO LACTATE DEHYDROGENASE-B - CHARACTERIZATION OF THE LACTATE DEHYDROGENASE-B SUPPRESSOR PATHWAY [J].
BAXEVANIS, CN ;
ISHII, N ;
NAGY, ZA ;
KLEIN, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 156 (03) :822-833
[10]   CHIMERIC TUMOR-NECROSIS-FACTOR RECEPTORS WITH CONSTITUTIVE SIGNALING ACTIVITY [J].
BAZZONI, F ;
ALEJOS, E ;
BEUTLER, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5376-5380